Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for tough breast cancer: experimental drug EP0062 enters human trials

NCT ID NCT05573126

Recruiting now Disease control Sponsor: Ellipses Pharma Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug called EP0062, alone or with standard treatments, in people with a certain type of advanced breast cancer (AR+/HER2-) that has returned or spread. The main goals are to find the safest dose and see if it helps shrink tumors. About 95 adults are taking part in this early-phase trial.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HORMONE RECEPTOR POSITIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HORMONE RECEPTOR POSITIVE BREAST CANCER HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER METASTATIC BREAST CANCER

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Henry Ford Hospital

    RECRUITING

    Detroit, Michigan, 48202, United States

  • Hospital 12 de Octubre

    RECRUITING

    Usera, Madrid, 28041, Spain

  • Hospital Universitari Vall d'Hebron (VHIO)

    RECRUITING

    Barcelona, 08035, Spain

  • Hospital Universitario Ramón y Cajal

    RECRUITING

    Madrid, 28034, Spain

  • Massachusetts General Hospital

    RECRUITING

    Boston, Massachusetts, 02114, United States

  • Moffitt Cancer Center

    RECRUITING

    Tampa, Florida, 33612, United States

  • NEXT Oncology Hospital Quironsalud

    RECRUITING

    Madrid, 28223, Spain

  • Sarah Cannon Research Institute

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • Sarah Cannon Research Institute UK

    RECRUITING

    London, London, W1G 6AD, United Kingdom

  • Texas Oncology Baylor University Medical Center

    RECRUITING

    Dallas, Texas, 75246, United States

  • The Christie NHS Foundation Trust

    RECRUITING

    Manchester, Wilmslow Rd, M20 4BX, United Kingdom

  • The Clatterbridge Cancer Centre

    RECRUITING

    Liverpool, CH63 4JY, United Kingdom

  • Virginia Cancer Specialists

    RECRUITING

    Fairfax, Virginia, 22031, United States

  • Yale School of Medicine

    COMPLETED

    New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.